Products Are Launched by Drug Makers Camber, Par and Teva.
NEW YORK -- Generic drug companies have rolled out a number of new products.
Teva Pharmaceutical Industries Ltd. this month launched a generic version of Letairis (ambrisentan) tablets, 5 mg and 10 mg, in the U.S. Ambrisentan is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension to improve exercise ability and delay clinical worsening. In combination with tadalafil, ambrisentan is indicated to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. For all female patients, ambrisentan tablets are only available through a restricted program due to the risk of fetal harm.
In April, Par Pharmaceutical, an operating company of Endo International PLC, began shipping an authorized generic version of Merck & Co.'s Proventil (albuterol sulfate) HFA inhalation aerosol, 120 meg. Endo's subsidiary Endo Procurement Operations Ltd. entered into an exclusive U.S. supply and distribution agreement with a subsidiary of Merck, allowing Par to launch and distribute the authorized generic.
Earlier this spring, Camber Pharmaceuticals added tadalafil tablets to its growing portfolio of products. Tadalafil is the generic version of Cialis from Eli Lilly and Co. and is used to treat male sexual function problems. Tadalafil tablets are available in 30-count bottles in strengths of 2.5 mg, 5 mg,10 mg and 20 mg.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Generic Drugs|
|Publication:||Chain Drug Review|
|Date:||May 13, 2019|
|Previous Article:||FDA Approves First Generic Naloxone Hydrochloride Nasal Spray.|
|Next Article:||Groups decry drug price rule.|